NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: In a previous study, iPS cells generated from CML patient-derived tumors exhibited an acquired resistance to receptor tyrosine kinase-targeted inhibition with imatinib despite unremitting expression of the BCR-ABL oncogene (Kumano et al., 2012).